title: Steroid sulfatase inhibitors: promising new therapy for breast cancer.
abstract: Manipulation of the hormone oestrogen has been used for decades to treat hormone-dependent breast cancer. Currently, aromatase inhibitors (AIs) are used as first-line therapy against early and metastatic breast cancer in post-menopausal women. Despite these advances, several patients eventually experience a relapse of breast cancer and declined clinical response to treatment. As per recent findings, steroid sulfatase (STS) has emerged as a novel therapy target. This review aims at summarising the emerging field of STS inhibitor development and highlighting current findings from pre-clinical and clinical trials. The recently-developed dual-targeting compounds, such as dual aromatase-sulfatase inhibitors (DASI), have shown encouraging preclinical results and represent important new treatments for hormone-dependent breast cancer.
authors.affiliation: MBS Biomedical Sciences, University of Guelph, Guelph, Ontario. hsadozai@uoguelph.ca
authors.forename: Hassan
authors.initials: H
authors.lastname: Sadozai
mesh_terms: D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001378:Azasteroids / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000378:metabolism; D003374:Coumarins / Q000627:therapeutic use*; D055808:Drug Discovery; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004967:Estrogens / Q000096:biosynthesis; D005260:Female; D006801:Humans; D043266:Steryl-Sulfatase / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000627:therapeutic use*; D013451:Sulfonic Acids
chemical_list: D047072:Aromatase Inhibitors; D001378:Azasteroids; D003374:Coumarins; D004791:Enzyme Inhibitors; D004967:Estrogens; C515227:STX 213; D013449:Sulfonamides; D013451:Sulfonic Acids; C520511:irosustat; D043266:Steryl-Sulfatase